Syed Sajidul Islam

Syed Sajidul Islam

Auto-generated profile, based on publicly available information

Syed Sajidul Islam

Department of Biotechnology and Genetic Engineering, Faculty of Biological Sciences, Jahangirnagar University, Savar, Dhaka, Bangladesh

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2020 in Immunobiology
Verified
Journal Article
Closed access
MUMd. Asad Ullah
Md. Asad Ullah
BSBishajit Sarkar
Bishajit Sarkar
SISyed Sajidul Islam
Syed Sajidul Islam

13 August 2020 in Journal of Receptors and Signal Transduction
Verified
Journal Article
Closed access
BSBishajit Sarkar
Bishajit Sarkar
MUMd. Asad Ullah
Md. Asad Ullah
SISyed Sajidul Islam
Syed Sajidul Islam
MD. Hasanur RahmanMD. Hasanur Rahman
MD. Hasanur Rahman
Yusha ArafYusha Araf
Yusha Araf
Cancer is caused by a variety of pathways, involving numerous types of enzymes. Among them three enzymes i.e. Cyclin-dependent kinase-2 (CDK-2), Human topoisomerase IIα, and Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) are three of the most common enzymes that are involved in the cancer development. Although many chemical drugs are already available in the market for cancer treatment, plant sources are known to contain a wide variety of agents that are proved to possess potential anticancer activity. In this experiment, total thirty phytochemicals were analyzed against the mentioned three enzymes using different tools of bioinformatics and in silico biology like molecular docking study, drug likeness property experiment, ADME/T test, PASS prediction, and P450 site of metabolism prediction as well as DFT calculation to determine the three best ligands among them that have the capability to inhibit the mentioned enzymes. From the experiment, Epigallocatechin gallate was found to be the best ligand to inhibit CDK-2, Daidzein showed the best inhibitory activities towards the Human topoisomerase IIα, and Quercetin was predicted to be the best agent against VEGFR-2. They were also predicted to be quite safe and effective agents to treat cancer. However, more in vivo and in vitro analyses are required to finally confirm their safety and efficacy in this regard.

3 January 2020 in medRxiv
Verified
Preprint
Open access
PDF file
MUMd. Asad Ullah
Md. Asad Ullah
BSBishajit Sarkar
Bishajit Sarkar
SISyed Sajidul Islam
Syed Sajidul Islam
Ebola virus is a highly pathogenic RNA virus that causes haemorrhagic fever in human. With very high mortality rate, Ebola virus is considered as one of the dangerous viruses in the world. Although, the Ebola outbreaks claimed many lives in the past, no satisfactory treatment or vaccine have been discovered yet to fight against Ebola. For this reason, in this study, various tools of bioinformatics and immunoinformatics were used to design possible vaccines against Zaire Ebola virus strain Mayinga-76. To construct the vaccine, three potential antigenic proteins of the virus, matrix protein VP40, envelope glycoprotein and nucleoprotein were selected against which the vaccines would be designed. The MHC class-I, MHC class-II and B-cell epitopes were determined and after robust analysis through various tools and molecular docking analysis, three vaccine candidates, designated as EV-1, EV-2 and EV-3, were constructed. Since the highly conserved epitopes were used for vaccine construction, these vaccine constructs are also expected to be effective on other strains of Ebola virus like strain Gabon-94 and Kikwit-95. Next, the molecular docking study on these vaccine constructs were analyzed by molecular docking study and EV-1 emerged as the best vaccine construct. Later, molecular dynamics simulation study revealed the good performances as well as good stability of the vaccine protein. Finally, codon adaptation and in silico cloning were conducted to design a possible plasmid (pET-19b plasmid vector was used) for large scale, industrial production of the EV-1 vaccine.

13 January 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
BSBishajit Sarkar
Bishajit Sarkar
MUMd. Asad Ullah
Md. Asad Ullah
SISyed Sajidul Islam
Syed Sajidul Islam
HRHasanur Rahman
Hasanur Rahman
Cancer is caused by a variety of pathways, involving numerous types of enzymes, among them three enzymes: Cyclin dependent kinase-2 (CDK-2), Human topoisomerase IIα and Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) are three most common enzymes that are involved in the cancer development. Although many chemical drugs are available in the market, plant sources are known to contain a wide variety of agents that are known to possess anticancer activity. In this experiment, total thirty compounds were analysed against the mentioned enzymes using different tools of bioinformatics andin silicobiology like molecular docking study, druglikeness property experiment, ADME/T test, PASS prediction and P450 site of metabolism prediction as well as DFT calculations to determine three best ligands that have the capability to inhibit the mentioned enzymes. Form the experiment, Epigallocatechin gallate was found to be the best ligand to inhibit CDK-2, Daidzein showed best inhibitory activities towards Human topoisomerase IIα and Quercetin was predicted to be the best agent against VEGFR-2. They were also predicted to be quite safe and effective agents to treat cancer. However, morein vivoandin vitroanalysis are required to confirm their safety and efficacy in this regard.

4 January 2021 in Journal of Contemporary Studies in Epidemiology and Public Health
Verified
Journal Article
Open access
PDF file
SISyed Sajidul Islam
Syed Sajidul Islam
SASayka Alam
Sayka Alam
TRTiluttoma Khan Rajib
Tiluttoma Khan Rajib
NANasrin Akhter
Nasrin Akhter
ZIZahidul Islam
Zahidul Islam
A highly pathogenic viral infection with several symptoms have been reported such as fever, cough, breathing difficulty, fatigue, headache, failure of taste or smell sensation, sore throat, congestion and diarrhoea in December, 2019 in Wuhan, China. In 30th January, 2020 World Health Organization (WHO) declared the outbreak of coronavirus disease to be a Public Health Emergency of global Concern. This virus is highly contagious and can be transmitted after close contact with an infected patient, and has quickly spread globally. In this pandemic, several types of drugs, non-drugs treatment, and their combination are being used to manage the coronavirus disease (COVID-19) affected patients which caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although none of them are officially recommended by any national and international committee such as U.S. Food and Drug Administration (USFDA) because the efficacy and the safety aspects of these treatments are still unidentified and extensively investigated. Different types of potential pharmacotherapy and treatments such as antimalarial, antiviral, antibiotics and many more are presently undertaking clinical-trials to prove their effectiveness in COVID-19 and some of them also showing promising results. This narrative review article summarizes some potential drugs used for the symptoms of coronavirus disease such as antivirals, antibiotics, antimalarial, anti-inflammatory and possible treatments such as neutralizing antibodies from convalescent plasma, umbilical cord mesenchymal stem cells (UC-MSCs) against SARS-CoV-2.